Free Trial

BridgeBio Pharma (BBIO) Competitors

BridgeBio Pharma logo
$23.41
-0.38 (-1.60%)
(As of 10/31/2024 ET)

BBIO vs. BHVN, BPMC, TPTX, PRGO, FOLD, SMMT, GMAB, VTRS, RDY, and SRPT

Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Biohaven (BHVN), Blueprint Medicines (BPMC), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Amicus Therapeutics (FOLD), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "medical" sector.

BridgeBio Pharma vs.

Biohaven (NYSE:BHVN) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Biohaven received 231 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 70.43% of users gave BridgeBio Pharma an outperform vote while only 66.72% of users gave Biohaven an outperform vote.

CompanyUnderperformOutperform
BiohavenOutperform Votes
393
66.72%
Underperform Votes
196
33.28%
BridgeBio PharmaOutperform Votes
162
70.43%
Underperform Votes
68
29.57%

Biohaven has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.

In the previous week, BridgeBio Pharma had 4 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for BridgeBio Pharma and 1 mentions for Biohaven. BridgeBio Pharma's average media sentiment score of 0.30 beat Biohaven's score of -0.07 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biohaven
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
BridgeBio Pharma
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 24.7% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biohaven has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven$462.51M9.75-$408.17M-$6.83-7.48
BridgeBio Pharma$219.12M20.82-$643.20M-$2.63-9.22

Biohaven has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -207.11%. BridgeBio Pharma's return on equity of 0.00% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
BiohavenN/A -212.83% -157.42%
BridgeBio Pharma -207.11%N/A -76.71%

Biohaven presently has a consensus price target of $61.92, indicating a potential upside of 25.08%. BridgeBio Pharma has a consensus price target of $47.50, indicating a potential upside of 95.80%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Biohaven.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven
0 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
3.07
BridgeBio Pharma
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.87

Summary

BridgeBio Pharma beats Biohaven on 10 of the 18 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBIO vs. The Competition

MetricBridgeBio PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.56B$7.13B$5.37B$8.41B
Dividend YieldN/A8.77%5.21%4.20%
P/E Ratio-9.2216.48140.7917.72
Price / Sales20.82254.251,454.6778.04
Price / CashN/A50.1638.9433.56
Price / Book-3.145.674.744.59
Net Income-$643.20M$151.16M$115.38M$225.45M
7 Day Performance0.37%-1.32%-0.54%-0.23%
1 Month Performance-4.71%6.33%3.93%1.90%
1 Year Performance-6.84%40.64%39.33%33.46%

BridgeBio Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBIO
BridgeBio Pharma
4.5489 of 5 stars
$23.41
-1.6%
$47.50
+102.9%
-6.7%$4.40B$219.12M-8.90400Upcoming Earnings
BHVN
Biohaven
2.6998 of 5 stars
$50.80
-1.8%
$61.92
+21.9%
+82.7%$4.49B$462.51M-5.55239
BPMC
Blueprint Medicines
2.8885 of 5 stars
$82.49
-0.3%
$118.22
+43.3%
+64.2%$5.17B$362.80M-24.12640Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
TPTX
Turning Point Therapeutics
N/A$76.01
flat
N/A+0.0%$3.81B$30.83M-11.02250
PRGO
Perrigo
4.8781 of 5 stars
$26.26
+1.9%
$37.00
+40.9%
-6.2%$3.58B$4.43B-28.549,140Upcoming Earnings
FOLD
Amicus Therapeutics
4.4376 of 5 stars
$11.39
-1.1%
$17.13
+50.4%
+6.0%$3.37B$455.66M-29.21480Upcoming Earnings
Analyst Downgrade
SMMT
Summit Therapeutics
2.8409 of 5 stars
$21.42
-3.7%
$36.00
+68.1%
+868.8%$15.52B$700,000.00-93.13105Analyst Forecast
GMAB
Genmab A/S
4.6695 of 5 stars
$23.07
-0.3%
$45.20
+95.9%
-20.0%$15.27B$2.39B19.072,204Upcoming Earnings
Short Interest ↓
Positive News
High Trading Volume
VTRS
Viatris
3.1185 of 5 stars
$11.77
+0.1%
$14.00
+18.9%
+34.5%$14.05B$15.43B-21.4038,000Upcoming Earnings
RDY
Dr. Reddy's Laboratories
1.7217 of 5 stars
$75.16
-4.2%
$87.00
+15.8%
+14.4%$12.54B$288.51B18.7927,048Upcoming Earnings
SRPT
Sarepta Therapeutics
4.9424 of 5 stars
$130.30
+0.0%
$182.95
+40.4%
+18.7%$12.32B$1.50B289.561,314Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:BBIO) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners